Sugi Predict

Sugi Predict / Compounds / SCHEMBL391585

SCHEMBL391585

SCHEMBL391585

NC(CCS(N)(=O)=O)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.41
▸ CA2 P00918 3/20 0.41
▸ GABBR2 O75899 4/20 0.41
▸ GABBR1 Q9UBS5 4/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA13 Q8N1Q1 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CA5B Q9Y2D0 1/20 0.41
▸ ADRB2 P07550 1/20 0.41
▸ SCN4A P35499 2/20 0.38
▸ PTGES2 Q9H7Z7 2/20 0.38
▸ CYP2C9 P11712 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390880 0.82 GABBR2 (0.49) CA1CA2GABBR2GABBR1CA9
SCHEMBL27301528 0.81 GABBR2 (0.41) CA1CA2GABBR2GABBR1CA9
SCHEMBL12497701 0.81 GBA1 (0.47) CA1CA2CA9CA5ASCN4A
SCHEMBL1534396 0.76 SLC6A4 (0.50) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL16649759 0.76 SLC6A4 (0.50) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL22053372 0.74 ADRB2 (0.48) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL20544852 0.73 ROCK2 (0.46) —
SCHEMBL390688 0.73 KIF11 (0.41) CA1CA2GABBR2GABBR1ADRB2
SCHEMBL390400 0.72 ADRB2 (0.46) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL391358 0.72 ADRB2 (0.46) GABBR2GABBR1ADRB2SCN4ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
CN-101861321-A Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2010-10-13 — — CN disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CA1 3988/4885CA2 1925/4885GABBR2 2327/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CA1 3988/4885CA2 1925/4885GABBR2 2327/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CA1 3988/4885CA2 1925/4885GABBR2 2327/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CA1 4458/4885CA2 2920/4885GABBR2 2682/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CA1 3988/4885CA2 1925/4885GABBR2 2327/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CA1 3988/4885CA2 1925/4885GABBR2 2327/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CA1 3988/4885CA2 1925/4885GABBR2 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.